← All trials
NCT06556368
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 23, 2024
- Primary completion
- Jan 31, 2026
- Completion date
- Jan 31, 2026
- First posted
- Aug 16, 2024
- Last posted
- Oct 29, 2024
- Enrollment
- 675
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kodiak Sciences IncLead sponsor
- Kodiak Sciences IncOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.